Biosimilar filgrastim (Leucostim((R))) was shown to be similar in terms of efficacy and safety in hematopoietic progenitor cell mobilization (HPCM) compared to originator filgrastim (Neupogen((R))) and lenograstim (Granocyte((R))) in healthy donors and chemomobilization settings. Here we report our retrospective experience with Leucostim((R)) (n: 43) compared to Neupogen((R)) (n: 71) and Granocyte((R)) (n: 32) in steady-state mobilization of patients presenting with Hodgkin lymphoma, non-Hodgkin lymphoma and multiple myeloma. The median age of patients on Leucostim((R)) (56) arm was significantly higher compared to patients who received Neupogen((R)) (50) and Granocyte((R)) (49) (p: 0.039). Patients who underwent HPCM with Leucostim((R)) received less chemotherapy lines (p: 0.026) and courses (p: 0.046) compared to others. Otherwise the study cohort was homogenous in terms of gender, primary diagnosis and various risk factors for mobilization failure. Mobilization failure was defined as failure to achieve a minimum threshold (10/mu L) for peripheral blood CD34+ cell concentration to initiate leukapheresis or 0.5x10(6)/kg, 0.8x10(6)/kg and 2x10(6)/kg CD34+ cells in first, second and fourth days of apheresis, respectively. The study groups were similar in terms of median number of CD34+ progenitor cell yield (x10(6)/kg) (Neupogen((R)): 6.18, Granocyte((R)): 6.2 and Leucostim((R)): 6.2) (p: 0.959) and median number of leukapheresis sessions (p: 0.615). The treatment arms were also similar in terms of mobilization failure (Neupogen((R)) 11.3% - Granocyte((R)) 21.9% - Leucostim((R)) 16.3%; p: 0.366). No patient experienced any severe adverse effect during HPCM. Leucostim((R)) is equally effective and safe in HPCM compared to originator G-CSF (Neupogen((R))) and lenograstim (Granocyte((R))) in steady-state HPCM setting. (C) 2017 Elsevier Ltd. All rights reserved.